CIK 0001517022 · Large accelerated filer
Akebia Therapeutics, Inc.
Sign in to watch- Ticker
- AKBA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208756903
- Phone
- 617-871-2098
- Business address
- 180 THIRD AVENUE, FLOOR 2, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-09 | Malabre Richard C SVP, Chief Accounting Officer | Option exercise 10b5-1 | +15,000 | $1.68 | $25K | 281,914 |
| 2025-06-09 | Malabre Richard C SVP, Chief Accounting Officer | Sale 10b5-1 | −15,000 | $4.01 | $60K | 266,914 |
| 2025-06-09 | Malabre Richard C SVP, Chief Accounting Officer | Option exercise · Stock Option (Right to buy) 10b5-1 | −15,000 | 321,000 | ||
| 2025-06-04 | Malabre Richard C SVP, Chief Accounting Officer | Sale 10b5-1 | −13,334 | $3.53 | $47K | 266,914 |
| 2025-03-03 | Butler John P. CEO and President | Sale 10b5-1 | −46,409 | $1.83 | $85K | 2,557,921 |
| 2025-03-03 | Burke Steven Keith SVP, Chief Medical Officer | Sale 10b5-1 | −7,144 | $1.83 | $13K | 809,090 |
| 2025-02-03 | Butler John P. CEO and President | Sale 10b5-1 | −46,268 | $2.10 | $97K | 2,702,312 |
| 2025-02-03 | Butler John P. CEO and President | Sale 10b5-1 | −97,982 | $2.10 | $206K | 2,604,330 |
| 2025-02-03 | Burke Steven Keith SVP, Chief Medical Officer | Sale 10b5-1 | −23,270 | $2.10 | $49K | 843,470 |
| 2025-02-03 | Burke Steven Keith SVP, Chief Medical Officer | Sale 10b5-1 | −27,236 | $2.10 | $57K | 816,234 |
| 2025-02-03 | Malabre Richard C SVP, Chief Accounting Officer | Sale 10b5-1 | −30,202 | $2.10 | $63K | 280,248 |
| 2025-02-03 | Grund Nicholas Chief Commercial Officer | Sale 10b5-1 | −55,621 | $2.10 | $117K | 442,579 |
| 2025-01-31 | Butler John P. CEO and President | Grant or award 10b5-1 | +701,000 | 2,748,580 | ||
| 2025-01-31 | Butler John P. CEO and President | Grant or award · Performance Stock Units 10b5-1 | +350,500 | 350,500 | ||
| 2025-01-31 | Butler John P. CEO and President | Grant or award · Stock Option (Right to buy) 10b5-1 | +1,051,400 | 1,051,400 | ||
| 2025-01-31 | Burke Steven Keith SVP, Chief Medical Officer | Grant or award 10b5-1 | +194,900 | 866,740 | ||
| 2025-01-31 | Burke Steven Keith SVP, Chief Medical Officer | Grant or award · Stock Option (Right to buy) 10b5-1 | +292,300 | 292,300 | ||
| 2025-01-31 | Malabre Richard C SVP, Chief Accounting Officer | Grant or award 10b5-1 | +85,000 | 310,450 | ||
| 2025-01-31 | Malabre Richard C SVP, Chief Accounting Officer | Grant or award · Stock Option (Right to buy) 10b5-1 | +128,000 | 128,000 | ||
| 2025-01-31 | Grund Nicholas Chief Commercial Officer | Grant or award 10b5-1 | +194,900 | 498,200 |
Page 4 of 21 · 405 trades